NewsVandana Singh
Monte Rosa Therapeutics
GLUE · NASDAQ
$11.36+$0.70 (+6.57%)TodayMarket closed ·
Prev close $10.66
Latest news
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
- NewsMohd Haider
GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
- News
10 Health Care Stocks Whale Activity In Today's Session
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
- News
Monte Rosa Therapeutics Q4 EPS $(0.55) Misses $(0.33) Estimate, Sales $2.781M Miss $15.506M Estimate
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
- NewsAvi Kapoor
Crude Oil Down 2%; ISM Services PMI Surges In December
- NewsAvi Kapoor
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
- News
Market-Moving News for January 7th
- NewsVandana Singh
Why Is Monte Rosa Stock Trading Higher Today?
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
- NewsAvi Kapoor
Dave & Buster's Entertainment Posts Downbeat Results, Joins Adtran Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket
- NewsVandana Singh
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
- News
Market-Moving News for Sept 15
- News
Monte Rosa Therapeutics To Collaborate With Novartis To Develop Novel Degraders For Immune-Mediated Diseases
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- NewsVandana Singh
Why Is Monte Rosa Therapeutics Stock Surging On Monday?
- News
Market-Moving News for October 28th
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.